INIS (Radnostix) Non Operating Income: $0.31 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Radnostix Non Operating Income?

Radnostix INIS Non Operating Income is $0.31 Mil as of Jun. 2026. The stock has 3 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Radnostix's Non Operating Income for the three months ended in Jun. 2026 was $0.02 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $0.31 Mil.

Radnostix Non Operating Income Related Terms

Radnostix Non Operating Income Historical Data

* Premium members only.

The historical data trend for Radnostix's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radnostix Non Operating Income Chart

Radnostix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 2.11 0.16 0.21 0.31

Radnostix Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.21 0.03 0.02

Radnostix Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $0.31 Mil mean?
Radnostix (INIS) has a Non Operating Income of $0.31 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Radnostix and its competitors.
Is Radnostix's Non Operating Income too high?
Radnostix's current Non Operating Income is $0.31 Mil.
How does Radnostix's Non Operating Income compare to RMTI and MRMD?
Radnostix's Non Operating Income of $0.31 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Drug Manufacturers company?
A good Non Operating Income depends on the Drug Manufacturers industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Radnostix and its competitors. Radnostix's current Non Operating Income is $0.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radnostix stock overvalued right now?
Based on GuruFocus' analysis, Radnostix (INIS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.06 — trading 48% above its estimated fair value. The current Non Operating Income is $0.31 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Radnostix (INIS), the current Non Operating Income is $0.31 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radnostix Business Description

Address 4137 Commerce Circle, Idaho Falls, ID, USA, 83401
Radnostix Inc manufactures a wide range of radioisotope-focused products used in a variety of medical and industrial applications. The company produces generic sodium iodide I-131 drug product, produces a variety of cobalt-60 products, and is in development to manufacture and sell medical devices for the nuclear medicine industry. Its business consists of five reportable segments, which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The majority of the revenue is derived from the Theranostics Products segment, which produces and distributes various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications.